for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tandem Diabetes Care Inc

TNDM.OQ

Latest Trade

93.64USD

Change

0.34(+0.36%)

Volume

49,121

Today's Range

93.13

 - 

95.00

52 Week Range

43.76

 - 

123.71

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
93.30
Open
94.05
Volume
49,121
3M AVG Volume
17.33
Today's High
95.00
Today's Low
93.13
52 Week High
123.71
52 Week Low
43.76
Shares Out (MIL)
62.19
Market Cap (MIL)
5,704.49
Forward P/E
-127.51
Dividend (Yield %)
--

Next Event

Q4 2020 Tandem Diabetes Care Inc Earnings Release

Latest Developments

More

Tandem Diabetes Care Announces Q3 Sales $123.6 Mln

Tandem Diabetes Reports Qtrly Net Loss Per Share Of $0.45

Medtronic And Tandem Diabetes Care Enter Into Patent Cross-License Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.

Industry

Medical Equipment & Supplies

Contact Info

11075 Roselle St

SAN DIEGO, CA

92121-1204

United States

+1.858.3666900

https://www.tandemdiabetes.com/

Executive Leadership

Kim D. Blickenstaff

Chairman of the Board

John F. Sheridan

President, Chief Executive Officer, Director

Leigh A. Vosseller

Chief Financial Officer, Executive Vice President, Treasurer

Susan M. Morrison

Executive Vice President, Chief Administrative Officer

David B. Berger

Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary

Key Stats

2.13 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.2K

2019

0.4K

2020(E)

0.5K
EPS (USD)

2017

-13.410

2018

-2.550

2019

-0.420

2020(E)

-0.719
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.99
Price To Book (MRQ)
17.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
60.98
LT Debt To Equity (MRQ)
60.98
Return on Investment (TTM)
-12.83
Return on Equity (TTM)
-10.09

Latest News

Latest News

BRIEF-Medtronic And Tandem Diabetes Care Enter Into Patent Cross-License Agreement

* MEDTRONIC AND TANDEM DIABETES CARE ENTER INTO PATENT CROSS-LICENSE AGREEMENT

BRIEF-Abbott, Tandem Diabetes Care Advance Development of Technologies for Insulin Delivery Systems

* ABBOTT - COS PARTNER TO INTEGRATE ABBOTT'S FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING TECHNOLOGY WITH TANDEM'S INSULIN DELIVERY PRODUCTS Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care Acquires Sugarmate, A Popular Mobile App For People With Diabetes

* TANDEM DIABETES CARE ACQUIRES SUGARMATE, A POPULAR MOBILE APP FOR PEOPLE WITH DIABETES

BRIEF-Tandem Diabetes Announces Expanded Pediatric Indication Of The TSlim X2 Insulin Pump

* TANDEM DIABETES CARE ANNOUNCES EXPANDED PEDIATRIC INDICATION OF THE T:SLIM X2 INSULIN PUMP WITH CONTROL-IQ ADVANCED HYBRID CLOSED-LOOP TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care Says Richard P. Valencia Notified He Intends To Commence Service As Chairman & CEO Of A Privately Held Company

* TANDEM DIABETES CARE - RICHARD P. VALENCIA NOTIFIED HE INTENDS TO COMMENCE SERVICE AS CHAIRMAN & CEO OF A PRIVATELY HELD COMPANY

BRIEF-Tandem Diabetes Care Announces Pricing Of $250 Mln Of Convertible Senior Notes Due 2025

* TANDEM DIABETES CARE ANNOUNCES PRICING OF $250.0 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025

BRIEF-Tandem Diabetes Care Announces Proposed Offering Of $250.0 Million Of Convertible Senior Notes Due 2025

* TANDEM DIABETES CARE ANNOUNCES PROPOSED OFFERING OF $250.0 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025

BRIEF-Tandem Diabetes Care Announces Security Incident With Five Employee Email Accounts

* TANDEM DIABETES CARE ANNOUNCES SECURITY INCIDENT WITH FIVE EMPLOYEE EMAIL ACCOUNTS

BRIEF-Tandem Diabetes Care Reports Qtrly Earnings Per Share $0.04

* TANDEM DIABETES CARE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND 2020 FINANCIAL GUIDANCE

U.S. FDA approves Tandem's predictive insulin pump software

The U.S. Food and Drug Administration on Friday granted approval for Tandem Diabetes Care's software program that uses readings from a continuous glucose monitor to predict and deliver corrective doses of insulin to patients using the company's t:slim X2 insulin pump.

U.S. FDA approves Tandem's predictive insulin pump software

The U.S. Food and Drug Administration on Friday granted approval for Tandem Diabetes Care's software program that uses readings from a continuous glucose monitor to predict and deliver corrective doses of insulin to patients using the company's t:slim X2 insulin pump.

BRIEF-Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump

* TANDEM DIABETES CARE-ANNOUNCED RECEIPT OF CE MARK APPROVAL FOR T:SLIM X2 INSULIN PUMP WITH DEXCOM G5® MOBILE CONTINUOUS GLUCOSE MONITORING INTEGRATION

BRIEF-Tandem Diabetes Care Files For Mixed Shelf Of Up To $100 Mln

* TANDEM DIABETES CARE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source : https://bit.ly/2JtPqwk Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Tandem Diabetes Care Reports Qtrly Net Loss Per Share, Basic And Diluted Of $1.82

* TANDEM DIABETES CARE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Tandem Diabetes Care Announces Insulin Pump Products Distribution Agreements In Australia And New Zealand

* TANDEM DIABETES CARE SAYS ANNOUNCES AGREEMENTS FOR DISTRIBUTION OF INSULIN PUMP PRODUCTS IN AUSTRALIA AND NEW ZEALAND Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care Q1 Sales $27 Mln Vs I/B/E/S View $25 Mln

* TANDEM DIABETES CARE ANNOUNCES PRELIMINARY FIRST QUARTER 2018 RESULTS

BRIEF-Tandem Diabetes Care And Movi SpA Announce Agreement For Distribution Of Insulin Pump Products In Italy

* TANDEM DIABETES CARE AND MOVI SPA ANNOUNCE AGREEMENT FOR DISTRIBUTION OF INSULIN PUMP PRODUCTS IN ITALY

BRIEF-Tandem Diabetes Care Q4 Sales $40.3 Million

* SALES FOR Q1 OF 2018 ARE ESTIMATED TO BE 18 PERCENT - 19 PERCENT OF ANNUAL SALES

BRIEF-Tandem Diabetes Care Applies For Health Canada Medical Device License

* TANDEM DIABETES CARE APPLIES FOR HEALTH CANADA MEDICAL DEVICE LICENSE

BRIEF-Tandem Diabetes Care Files For Offering Of 13.5 Mln Shares Of Co's Common Stock

* TANDEM DIABETES CARE FILES FOR OFFERING OF 13.5 MILLION SHARES OF CO'S COMMON STOCK, PAR VALUE $0.001 PER SHARE - SEC FILING Source text: (http://bit.ly/2nmA5Fh) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up